Michael Breen's Insider Trades & SAST Disclosures
Michael Breen's most recent trade in GT Biopharma Inc was a trade of 200,000 Common Stock done at an average price of $0.3 . Disclosure was reported to the exchange on Aug. 11, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Breen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| GT Biopharma Inc | Michael Breen | Director, Executive Chairman/Interim CEO | Grant, award, or other acquisition of securities at price $ 0.29 per share. | 11 Aug 2023 | 200,000 | 856,218 | - | 0.3 | 57,400 | Common Stock |
| GT Biopharma Inc | Michael Breen | Director, Executive Chairman/Interim CEO | Purchase of securities on an exchange or from another person at price $ 0.50 per share. | 11 Apr 2023 | 50,000 | 656,218 | - | 0.5 | 25,000 | Common Stock |
| GT Biopharma Inc | Michael Breen | Director, Exec Chairman and Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2023 | 500,000 | 500,000 | - | - | Option to purchase Common Stock | |
| GT Biopharma Inc | Michael Breen | Director, Exec. Chair. and Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 278,058 | 606,218 | - | 0 | Common Stock | |
| GT Biopharma Inc | Michael Breen | Director, Exec. Chair. and Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 50,000 | 50,000 | - | - | Option to purchase Common Stock | |
| GT Biopharma Inc | Michael Breen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 278,058 | 278,058 | - | 0 | Common Stock | |
| GT Biopharma Inc | Michael Breen | Director | 16 Feb 2021 | 100,000 | 0 | - | - | 10% Senior Convertible Debenture | ||
| GT Biopharma Inc | Michael Breen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 50,000 | 50,000 | - | - | Option to purchase Common Stock | |
| GT Biopharma Inc | Michael Breen | Director | 16 Feb 2021 | 40,243 | 318,301 | - | 3.4 | 136,826 | Common Stock | |
| GT Biopharma Inc | Michael Breen | Director | 16 Feb 2021 | 30,000 | 0 | - | - | 10% Senior Convertible Debenture | ||
| GT Biopharma Inc | Michael Breen | Director | 16 Feb 2021 | 9,859 | 328,160 | - | 3.4 | 33,521 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges